EDX Medical’s latest investor presentation is now available to watch, with founder and Chief Scientific Officer Professor Sir Chris Evans outlining the company’s progress in bringing advanced diagnostic tests and services to market.
Hosted by Investor Meet Company on 14 October 2026, the presentation provides an introduction to EDX Medical and its work to improve the early detection and treatment of cancer, cardiovascular conditions and infectious diseases.
Sir Chris discusses the company’s transition from product development to revenue generation, highlighting its growing portfolio of cancer diagnostics, chemotherapy sensitivity testing and liquid biopsy services. The presentation also covers EDX Medical’s rapid pneumonia test, currently used at Addenbrooke’s Hospital.
Corporate health screening is another key focus, including a contract with Arnold Clark Group covering its 8,500 employees and discussions with other major employers. These services aim to help identify health concerns earlier and support a more informed approach to employee wellbeing.
Looking ahead, the presentation explores plans for additional ovarian cancer, prostate cancer and sepsis tests in 2027, alongside opportunities to expand internationally through distribution and licensing partnerships.
Watch the recording below for an overview of EDX Medical’s diagnostic portfolio, commercial progress and plans for growth.
